Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast

Emerging Infectious Diseases

Volumn 20, Issue 1, 2014, Pages 45-53

  Boulware, David R ^a   Rolfes, Melissa A ^a   Rajasingham, Radha ^a,b   von Hohenberg, Maximilian ^a   Qin, Zhenpeng ^a   Taseera, Kabanda ^c   Schutz, Charlotte ^d,e   Kwizera, Richard ^b   Butler, Elissa K ^a   Meintjes, Graeme ^d,e   Muzoora, Conrad ^c   Bischof, John C ^a   Meya, David B ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^d GF Jooste Hospital   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CRYPTOCOCCAL ANTIGEN; FLUCONAZOLE; GOLD NANOPARTICLE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID CULTURE; CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; LATEX AGGLUTINATION TEST; MAJOR CLINICAL STUDY; MALE; MULTILOCUS SEQUENCE TYPING; RETROSPECTIVE STUDY; SEIZURE; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; UGANDA; VALIDATION STUDY;

CEREBROSPINAL FLUID; CRYPTOCOCCAL ANTIGEN; CRYPTOCOCCAL ANTIGEN LATEX AGGLUTINATION; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS SPP.; CULTURE; DIAGNOSTIC TECHNIQUES; FUNGI; HIV; INDIA INK MICROSCOPY; LASER THERMAL CONTRAST MEASUREMENT; LATERAL FLOW IMMUNOCHROMATOGRAPHIC ASSAY; POINT-OF-CARE SYSTEMS; SENSITIVITY; SOUTH AFRICA; SPECIFICITY; UGANDA; VALIDATION STUDIES;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, FUNGAL; CRYPTOCOCCUS; HUMANS; IMMUNOCHROMATOGRAPHY; MENINGITIS, CRYPTOCOCCAL; POINT-OF-CARE SYSTEMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84890946398     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2001.130906     Document Type: Article

References (38)

1. Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis. 2010;10:67. http://dx.doi.org/10.1186/1471-2334-10-67
2. Hakim JG, Gangaidzo IT, Heyderman RS, Mielke J, Mushangi E, Taziwa A, et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS. 2000;14:1401-7. http://dx.doi org/10.1097/ 00002030-200007070-00013
3. Cohen DB, Zijlstra EE, Mukaka M, Reiss M, Kamphambale S, Scholing M, et al. Diagnosis of cryptococcal and tuberculous meningitis in a resource-limited African setting. Trop Med Int Health. 2010;15:910-7. http://dx.doi.org/10.1111/j.1365-3156.2010.02565.x
4. Durski KN, Kuntz KM, Yasukawa K, Virnig BA, Meya DB, Boulware DR. Cost-effective diagnostic checklists for meningitis in resource-limited settings. J Acquir Immune Defic Syndr. 2013;63:e101-8. http://dx.doi.org/10.1097/QAI.0b013e31828e1e56
5. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525-30. http://dx.doi.org/10.1097/QAD.0b013e328322ffac
6. French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 2002;16:1031-8. http://dx.doi.org/10.1097/00002030-200205030-00009
7. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, Weidle PJ, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health. 2007;12:929-35. http://dx.doi.org/10.1111/j.1365-3156.2007.01874.x
8. World Health Organization. Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children, 2011 [cited 2012 May 31]. http://www. who.int/hiv/pub/cryptococcal_disease2011
9. Jarvis JN, Govender N, Chiller T, Park BJ, Longley N, Meintjes G, et al. Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Physicians AIDS Care (Chic). 2012;11:374-9. http://dx.doi. org/10.1177/1545109712459077
10. Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr. 2012;59:e85-91. http://dx.doi. org/10.1097/QAI.0b013e31824c837e
11. Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull. 2004;72:99-118. http://dx.doi.org/10.1093/bmb/ldh043
12. Kambugu A, Meya DB, Rhein J, O'Brien M, Janoff EN, Ronald AR, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008;46:1694-701. http://dx.doi.org/10.1086/587667
13. Kisenge PR, Hawkins AT, Maro VP, McHele JP, Swai NS, Mueller A, et al. Low CD4 count plus coma predicts cryptococcal meningitis in Tanzania. BMC Infect Dis. 2007;7:39. http://dx.doi. org/10.1186/1471-2334-7-39
14. Trachtenberg JD, Kambugu AD, McKellar M, Semitala F, Mayanja-Kizza H, Samore MH, et al. The medical management of central nervous system infections in Uganda and the potential impact of an algorithm-based approach to improve outcomes. Int J Infect Dis. 2007;11:524-30. http://dx.doi.org/10.1016/j.ijid.2007.01.014
15. Brouwer AE, Teparrukkul P, Pinpraphaporn S, Larsen RA, Chierakul W, Peacock S, et al. Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis. J Infect Dis. 2005;192:681-4. http://dx.doi.org/10.1086/432073
16. Taseera K, Siedner MJ, Klausner JD, Muzoora C, Boulware DR. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis. 2013;Oct 8. [Epub ahead of print].
17. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111 cases. Ann Intern Med. 1974;80:176-81. http://dx.doi.org/10.7326/0003-4819-80-2-176
18. Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, Musubire A, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med. 2010;7:e1000384. http://dx.doi.org/10.1371/journal.pmed.1000384
19. Qin Z, Chan WC, Boulware DR, Akkin T, Butler EK, Bischof JC. Significantly improved analytical sensitivity of lateral flow immunoassays by using thermal contrast. Angew Chem Int Ed Engl. 2012;51:4358-61. http://dx.doi.org/10.1002/anie.201200997
20. Boulware DR, Bonham SC, Meya DB, Wiesner DL, Park GS, Kambugu A, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis. 2010;202:962-70. http://dx.doi.org/10.1086/655785
21. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363:1764-7. http://dx.doi.org/10.1016/S0140-6736(04)16301-0
22. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. 2007;45:76-80. http://dx.doi.org/10.1086/518607
23. Wiesner DL, Moskalenko O, Corcoran JM, McDonald T, Rolfes MA, Meya DB, et al. Cryptococcal genotype influences immunologic response and human clinical outcome after meningitis. MBio. 2012;3:e00196-12. http://dx.doi.org/10.1128/mBio.00196-12
24. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011;53:1019-23. http://dx.doi.org/10.1093/cid/cir613
25. Gates-Hollingsworth MA, Kozel TR. Serotype sensitivity of a lateral flow immunoassay for cryptococcal antigen. Clin Vaccine Immunol. 2013;20:634-5. http://dx.doi.org/10.1128/CVI.00732-12
26. Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PM. Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol Assess. 2007;11:iii: ix-51.
27. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count ≤ 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51:448-55. http://dx.doi.org/10.1086/655143
28. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009;48:856-62. http://dx.doi.org/10.1086/597262
29. Joint Medical Store. Product catalogue. 2013 June 5, [cited 2013 Sep 1]. http://www.jms.co.ug/resources
30. Lindsley MD, Mekha N, Baggett HC, Surinthong Y, Autthateinchai R, Sawatwong P, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis. 2011;53:321-5. http://dx.doi.org/10.1093/cid/cir379
31. Binnicker MJ, Jespersen DJ, Bestrom JE, Rollins LO. Comparison of four assays for the detection of cryptococcal antigen. Clin Vaccine Immunol. 2012;19:1988-90. http://dx.doi.org/10.1128/CVI.00446-12
32. Hansen J, Slechta ES, Gates-Hollingsworth MA, Neary B, Barker AP, Bauman S, et al. Large-scale evaluation of the immuno-mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin Vaccine Immunol. 2013;20:52-5. http://dx.doi.org/10.1128/ CVI.00536-12
33. McMullan BJ, Halliday C, Sorrell TC, Judd D, Sleiman S, Marriott D, et al. Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLoS ONE. 2012;7:e49541. http://dx.doi.org/10.1371/journal.pone.0049541
34. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58:1-207.
35. Govender NP, Meintjes G, Bicanic T, Dawood H, Harrison TS, Jarvis JN, et al. Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: 2013 update. South African Journal of HIV Medicine. 2013;14:76-86. http://dx.doi.org/10.7196/sajhivmed.930
36. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291-322. http://dx.doi.org/10.1086/649858
37. Lortholary O, Poizat G, Zeller V, Neuville S, Boibieux A, Alvarez M, et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS. 2006;20:2183-91. http://dx.doi.org/10.1097/01. aids.0000252060.80704.68
38. Sungkanuparph S, Filler SG, Chetchotisakd P, Pappas PG, Nolen TL, Manosuthi W, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis. 2009;49:931-4. http://dx.doi.org/10.1086/605497